Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 2, 2023

Analysis of the expression and clinical significance of PGM5 in clear cell renal cell carcinoma based on the TCGA database

Download as PDF

DOI: 10.23977/medsc.2023.040209 | Downloads: 10 | Views: 397

Author(s)

Feiteng Liang 1, Hui Liang 1,2

Affiliation(s)

1 Guangdong Medical University, Zhanjiang 524000, China
2 Department of Urology, Longhua District People's Hospital, Longhua District, Shenzhen City, 518000, China

Corresponding Author

Hui Liang

ABSTRACT

To analyze the expression characteristics and clinical relevance of PGM5 in clear cell renal cell carcinoma based on the TCGA database. The differential expression of PGM5 and the association between PGM5 and clinical diagnosis and prognosis in clear cell renal cell carcinoma were analyzed based on the TCGA, GEIPIA, and Linkedomics databases. The R language was used to process and analyze data. The genes related to the expression of PGM5 were analyzed with the WebGestalt tool. The analysis based on the TCGA showed that the expression level of PGM5 mRNA in ccRCC tissues was lower than that in normal renal tissues. The Linkedomics database analysis showed that PGM5 mRNA is different expressed in the pathological Stage of the clear cell takes cell carcinoma (P < 0.05). The expression level tended to be downregulated with the happens of the pathological stage. PGM5 mRNA was differentially expressed in different T, N, and M stages (P<0.05). Survival analysis showed that PGM5 expression level was significantly associated with overall survival and disease-free survival in ccRCC patients. The diagnostic accuracy showed that the PGM5 expression had excellent diagnostic value by ROC curve analysis for distinguishing between ccRCC tissues and normal renal tissues. In addition, the expression level of PGM5 was positively correlated with that of PAPB, and PARM1, respectively, and negatively correlated with those of PMM2, NME1, and PDCD5. The enrichment analysis of genes associated with PGM5 expression was positively correlated with DNA replication and cell cycle and negatively correlated with those of cGMP-PKG and Rap1 signaling pathways. The expression level of PGM5 mRNA is associated with the pathological stage, T stage, N stage, M stage, and prognosis in patients with clear cell renal cell carcinoma. Therefore, PGM5 has the potential to become a diagnostic marker, as well as a therapeutic target of clear cell renal cell carcinoma.

KEYWORDS

Clear cell renal cell carcinoma, PGM5, TCGA database

CITE THIS PAPER

Feiteng Liang, Hui Liang, Analysis of the expression and clinical significance of PGM5 in clear cell renal cell carcinoma based on the TCGA database. MEDS Clinical Medicine (2023) Vol. 4: 54-63. DOI: http://dx.doi.org/10.23977/medsc.2023.040209.

REFERENCES

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. International Journal of Cancer, 2015, 136(5): E359-386.
[2] Guerra Liberal F D C, O 'Sullivan J M, McMahon S J, et al. Targeted Alpha Therapy: Current Clinical Applications[J]. Cancer Biotherapy & Radiopharmaceuticals, 2020, 35(6): 404-417.
[3] Edwards Y H, Putt W, Fox M, et al. A novel human phosphoglucomutase (PGM5) maps to the centromeric region of chromosome 9[J]. Genomics, 1995, 30(2): 350-353.
[4] Muenks A G, Stiers K M, Beamer L J. Sequence-structure relationships, expression profiles, and disease-associated mutations in the paralogs of phosphoglucomutase 1[J]. PloS One, 2017, 12(8): e0183563.
[5] Lee C H, Jeong S J, Yun S M, et al. Down-regulation of phosphoglucomutase 3 mediates sulforaphane-induced cell death in LNCaP prostate cancer cells[J]. Proteome Science, 2010, 8: 67.
[6] Sun J, Wang F, Zhou H, et al. Downregulation of PGM5 expression correlates with tumor progression and poor prognosis in human prostate cancer[J]. Discover. Oncology, 2022, 13(1): 63.
[7] Curtis M, Kenny H A, Ashcroft B, et al. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis[J]. Cell Metabolism, 2019, 29(1): 141-155.e9.
[8] Ran F, Zhang Y, Shi Y, miR-1224-3p Promotes Breast Cancer Cell Proliferation and Migration through PGM5-Mediated Aerobic Glycolysis[J]. Journal of Oncology, 2021, 2021: 5529770.
[9] Chen B, Zheng S, Jiang F. miR-1293 acts as a tumor promotor in lung adenocarcinoma via targeting phosphoglucomutase 5[J]. PeerJ, 2021, 9: e12140.
[10] Cancer Genome Atlas. Research Network, Weinstein J N, Collisson E A, et al. The Cancer Genome Atlas Pan-Cancer analysis project[J]. Nature Genetics, 2013, 45(10): 1113-1120.
[11] Vasaikar S V, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Research, 2018, 46(D1): D956-D963.
[12] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Research, 2017, 45(W1): W98-W102.
[13] Wang J, Vasaikar S, Shi Z, et al. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit[J]. Nucleic Acids Research, 2017, 45(W1): W130-W137.
[14] Lv C, Li Y, Zhang Q, et al. Low REST Expression Indicates a Biomarker of Poor Prognosis in Patients with Renal Cell Carcinoma[J]. BioMed Research International, 2021, 2021: 6682758.
[15] Chen J, Hua X, Chen H, et al. PKMYT1, exacerbating the progression of clear cell renal cell carcinoma, is implied as a biomarker for the diagnosis and prognosis[J]. Aging, 2021, 13(24): 25778-25798.
[16] Lin W, Chen X, Chen T, et al. C1QTNF6 as a Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma[J]. DNA and cell biology, 2020, 39(6): 1000-1011.
[17] Uzozie A C, Selevsek N, Wahlander A, et al. Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis[J]. Molecular & cellular proteomics: MCP, 2017, 16(3): 407-427.
[18] Jiao Y, Li Y, Jiang P, et al. PGM5: a novel diagnostic and prognostic biomarker for liver cancer[J]. PeerJ, 2019, 7: e7070.
[19] Charfi C, Levros L C, Edouard E, et al. Characterization and identification of PARM-1 as a new potential oncogene[J]. Molecular Cancer, 2013, 12: 84.
[20] Zhu Y, Dai B, Zhang H, et al. Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53  signaling axis[J]. Cancer Letters, 2016, 380(2): 369-374.
[21] Chen S, Yu M, Ju L, et al. The immune-related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation[J]. Cancer Cell International, 2021, 21(1): 119.
[22] Yamada Y, Arai T, Sugawara S, et al. Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma[J]. Cancer Science, 2018, 109(4): 1239-1253.
[23] Lodillinsky C, Fuhrmann L, Irondelle M, et al. Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance[J]. Oncogene, 2021, 40(23): 4019-4032.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4576
Visits: 198383

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.